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Purpose of the study
The purpose of the study was to assess virologic and
immunologic effectiveness of lopinavir/ritonavir in HIV-
infected adults who are antiretroviral (ARV) naïve, pro-
tease inhibitor (PI) naïve or PI-experienced but naïve to
lopinavir/ritonavir.
Methods
This is an ongoing 96-week, observational, open-label,
multicenter study. Patients were prescribed the standard
dose of lopinavir/ritonavir (400 mg/100 mg) twice a day.
Other ARV medications were prescribed at the discretion
of the physician according to usual clinical practice.
Summary of results
Of the 142 patients enrolled, 47.2% had not received any
previous ARV treatment (ARV-naïve), 19.0% have not
been treated with PI-based regimen (PI-naïve), and 31.7%
have been exposed to PI-based regimen with the excep-
tion of lopinavir/ritonavir (PI-experienced). The mean
(SD) age was 44.6 (9.5) years, 123 (86.6%) were male and
109 (76.8%) were Caucasian. The mean (SD) duration of
HIV disease was 4.3 (0.7) years. Of the 35 (25.6%)
patients discontinued, 13 withdrew due to adverse event
(AE). The virologic results after 48 weeks of treatment are
available for 106 patients (53 ARV-naive; 19 PI-naïve; 34
PI-non-naive). There were 34 (64.2%) ARV-naïve, 14
(73.7%) PI-naïve, and 22 (64.7%) PI-experienced
patients with HIV-RNA viral load < 50 copies/mL after 48
weeks of treatment. There were 116 patients included in
the immunologic analyses. Linear regression was per-
formed to estimate the CD4 cell counts at 48 weeks of
treatment. Mean (SD) change in absolute CD4 cell counts
between baseline and 48 weeks of treatment was 196.9
(52.0) (p < 0.001) in ARV-naïve, 110.8 (52.8) (p < 0.001)
in PI-naïve and 13.0 (78.0) (p = 0.513) in PI-experienced
patients. Of the 142 patients enrolled, none developed >6
protease resistance mutations. At the time of the analysis,
there were 171 AEs probably/possibly related to lopina-
vir/ritonavir reported by 70 out of 142 patients, 29 ARV-
naïve, 16 PI-naïve and 25 PI-experienced patients. Hyper-
cholesterolemia was reported by one ARV-naïve and one
PI-experienced patient who were not receiving lipid-low-
ering agents. Of the 17 serious AEs reported by three ARV-
naïve and four PI-experienced patients, 12 were probably
not/not related to study drug and none led to discontinu-
ation.
Conclusion
After 48 weeks of treatment in a clinical setting, lopinavir/
ritonavir is effective in achieving virologic control and
immunologic improvement in ARV-naïve, PI-naïve or PI-
experienced patients, with more significant immunologic
benefit in ARV and PI-naïve patients.
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